+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cervical Cancer Screening Market, Patients, Mortality Global Forecast by Tests Type (Pap Smear, HPV DNA, VIA), 19 Countries Analysis

  • ID: 5134047
  • Report
  • July 2020
  • Region: Global
  • 292 pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

Globally, cervical cancer is the most appearing cancer in women. Cervical cancer is most frequently diagnosed in women between the age of 35 and 44 with the average age of diagnosis being 50. In 2019, an estimated 283.15 million women were diagnosed with cervical cancer worldwide, and about 311,000 women died from the disease in 2018. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. There are three types of screening for identifying cervical cancer they are Pap Smear Tests, Human Papillomavirus Virus (HPV) Tests and Visual Inspection with Acetic Acid (VIA) Tests. These screenings are a key factor anticipated to boost the number of screening tests over the forecast period. Effective primary (HPV vaccination) approach (testing and treating precancerous lesions) will prevent most cervical cancer cases. According to this report, Cervical Cancer Screening Market is expected to be USD 16.5 Billion by 2026.

This report provides 19 Countries cervical cancer market analysis & forecast with numbers of screening & Mortality. In the United States, the medical community has made great strides in preventing and controlling cervical cancer. The reasons that influence world market dominance are the presence of technological advancements in terms of new diagnostic equipment, diagnostic procedures, favourable government policies related to reimbursement and screening techniques are expected to have a positive impact on the market. Cervical cancer is one of the leading causes of female cancer deaths in low- and middle-income countries.

COVID-19 impacts Global Cervical Cancer Screening Industry

The cervical cancer screening declined to meagre numbers due to pandemic coronavirus. Mostly non-urgent cervical cancer appointments have been cancelled in the wake of COVID-19. However, things started moving in the last two quarters, but it will not return to pre-COVID numbers this year. As preventive measures should put in place during the efforts of providing cervical cancer screening as directed by the health authorities. Read the complete analysis on how COVID-19 has affected the cervical cancer screening market and its future?

According to this report Cervical Cancer Market, Patients, Mortality Global Forecast by Tests (Pap Smear, HPV DNA, VIA), 19 Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia)

Cervical Cancer Screening Market & Population - the report studies all 3 types of Test

  • Pap Smear Tests Market
  • HPV DNA Tests Market
  • VIA Tests Market

Cervical Cancer Mortality Population

In this section number of deaths by cervical cancer in all the 19 countries from 2014 to 2020 has been captured. The report gives complete insights of Market, Screened Population & Mortality of 19 countries, which provides a general idea of worldwide countries analysis of Global Cervical Cancer Screening Industry.

1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
10. United States
11. Canada
12. Japan
13. Korea
14. Singapore
15. Malaysia
16. India
17. China
18. Thailand
19. Indonesia

Note: Product cover images may vary from those shown
2 of 4
1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Cervical Cancer Test (Screening) Population
4.1 Asia
4.2 Europe
4.3 North America
4.4 Rest of World

5. Global Cervical Cancer Test (Screening) Market
5.1 Pap Smear Test (Screening)
5.2 HPV DNA Test (Screening)

6. By Region - Global Cervical Cancer Test (Screening) Market Analysis
6.1 Asia
6.2 Europe
6.3 North America
6.4 Rest of World

7. Population Share - Global Cervical Cancer Test (Screening)
7.1 By Region
7.2 By Countries

8. Market Share - Global Cervical Cancer Test (Screening)
8.1 Region - Cervical Cancer Test (Screening)
8.2 Countries - Cervical Cancer Test (Screening)
8.3 Countries - Pap Smear Test (Screening)
8.4 Countries - HPV DNA Test (Screening)
8.5 Countries - VIA Test (Screening)

9. United Kingdom - Cervical Cancer Test Analysis
9.1 United Kingdom Cervical Cancer Test (Screening) Population & Forecast
9.1.1 United Kingdom Pap Smear Test Population
9.1.2 United Kingdom HPV DNA Test Population
9.2 United Kingdom Cervical Cancer Deaths
9.3 United kingdom Cervical Cancer Test (Screening) Market & Forecast
9.3.1 United Kingdom Pap Smear Test Market
9.3.2 United Kingdom HPV DNA Test Market

10. France - Cervical Cancer Test Analysis
10.1 France Cervical Cancer Test (Screening) Population & Forecast
10.1.1 France Pap Smear Test Population
10.1.2 France HPV DNA Test Population
10.2 France Cervical Cancer Mortality
10.3 France Cervical Cancer Test (Screening) Market & Forecast
10.3.1 France Pap Smear Test Market
10.3.2 France HPV DNA Test Market

11. Germany - Cervical Cancer Test Analysis
11.1 Germany Cervical Cancer Test (Screening) Population & Forecast
11.1.1 Germany Pap Smear Test Population
11.1.2 Germany HPV DNA Test Population
11.2 Germany Cervical Cancer Mortality
11.3 Market - Cervical Cancer Test (Screening)
11.3.1 Germany Pap Smear Test Market
11.3.2 Germany HPV DNA Test Market

12. Italy - Cervical Cancer Test Analysis
12.1 Cervical Cancer Test (Screening) Population & Forecast
12.1.1 Italy Pap Smear Test Population
12.1.2 Italy HPV DNA Test Population
12.2 Italy Cervical Cancer Mortality
12.3 Italy Cervical Cancer Test (Screening) Market & Forecast
12.3.1 Italy Pap Smear Test Market
12.3.2 Italy HPV DNA Test Market

13. Spain - Cervical Cancer Test Analysis
13.1 Spain Cervical Cancer Test (Screening) Population & Forecast
13.1.1 Spain Pap Smear Test Population
13.1.2 Spain HPV DNA Test Population
13.2 Spain Cervical Cancer Mortality
13.3 Spain Cervical Cancer Test (Screening) Market & Forecast
13.3.1 Spain Pap Smear Test Market
13.3.2 Spain HPV DNA Test Market

14. Sweden - Cervical Cancer Test Analysis
14.1 Sweden Cervical Cancer Test (Screening) Population & Forecast
14.1.1 Sweden Pap Smear Test Population
14.1.2 Sweden HPV DNA Test Population
14.2 Sweden Cervical Cancer Mortality
14.3 Cervical Cancer Test (Screening) Market & Forecast
14.3.1 Sweden Pap Smear Test Market
14.3.2 Sweden HPV DNA Test Market

15. Switzerland - Cervical Cancer Test Analysis
15.1 Switzerland Cervical Cancer Test (Screening) Population & Forecast
15.1.1 Switzerland Pap Smear Test Population
15.1.2 Switzerland HPV DNA Test Population
15.2 Switzerland Cervical Cancer Mortality
15.3 Switzerland Cervical Cancer Test (Screening) Market & Forecast
15.3.1 Switzerland Pap Smear Test Market
15.3.2 Switzerland HPV DNA Test Market

16. Norway - Cervical Cancer Test Analysis
16.1 Norway Cervical Cancer Test (Screening) Population & Forecast
16.1.1 Norway Pap Smear Test Population
16.1.2 Norway HPV DNA Test Population
16.2 Norway Cervical Cancer Mortality
16.3 Norway Cervical Cancer Test (Screening) Market & Forecast
16.3.1 Norway Pap Smear Test Market & Forecast
16.3.2 Norway HPV DNA Test Market

17. Netherlands - Cervical Cancer Test Analysis
17.1 Netherlands Cervical Cancer Test (Screening) Population & Forecast
17.1.1 Netherlands Pap Smear Test Population
17.1.2 Netherlands HPV DNA Test Population
17.2 Netherlands Cervical Cancer Mortality
17.3 Netherlands Cervical Cancer Test (Screening) Market & Forecast
17.3.1 Netherlands Pap Smear Test Market
17.3.2 Netherlands HPV DNA Test Market

18. United States - Cervical Cancer Test Analysis
18.1 United States Cervical Cancer Test (Screening) Population & Forecast
18.1.1 United States Pap smear Test Population
18.1.2 United States HPV DNA Test Population
18.2 United States Cervical Cancer Mortality
18.3 United States Cervical Cancer Test (Screening) Market
18.3.1 United States Pap Smear Test Market
18.3.2 United States HPV DNA Test Market

19. Canada - Cervical Cancer Test Analysis
19.1 Canada Cervical Cancer Test (Screening) Population & Forecast
19.1.1 Canada Pap smear Test Population
19.1.2 Canada HPV DNA Test Population
19.2 Canada Cervical Cancer Mortality
19.3 Canada Cervical Cancer Test (Screening) Market & Forecast
19.3.1 Canada Pap Smear Test Market
19.3.2 Canada HPV DNA Test Market

20. Japan - Cervical Cancer Test Analysis
20.1 Japan Cervical Cancer Test (Screening) Population & Forecast
20.1.1 Japan Pap smear Test Population
20.1.2 Japan HPV DNA Test Population
20.2 Japan Cervical Cancer Mortality
20.3 Japan Cervical Cancer Test (Screening) Market & Forecast
20.3.1 Japan Pap Smear Test Market
20.3.2 Japan HPV DNA Test Market

21. South Korea - Cervical Cancer Tests Analysis
21.1 South Korea - Cervical Cancer Test (Screening) Population & Forecast
21.1.1 South Korea Pap Smear Test Population
21.1.2 Korea HPV DNA Test Population
21.2 Korea Cervical Cancer Mortality
21.3 Korea Cervical Cancer Test (Screening) Market & Forecast
21.3.1 Korea Pap Smear Test Market
21.3.2 Korea HPV DNA Test Market

22. Singapore - Cervical Cancer Tests Analysis
22.1 Singapore - Cervical Cancer Test (Screening) Population & Forecast
22.1.1 Singapore Pap Smear Test Population
22.1.2 Singapore HPV DNA Test Population
22.2 Singapore Cervical Cancer Test (Screening) Market & Forecast
22.2.1 Singapore Pap Smear Test Market
22.2.2 Singapore HPV DNA Test Market

23. Malaysia - Cervical Cancer Test Analysis
23.1 Malaysia - Cervical Cancer Test (Screening) Population & Forecast
23.1.1 Malaysia Pap Smear Test Population
23.1.2 Malaysia HPV DNA Test Population
23.2 Malaysia Cervical Cancer Test (Screening) Market & Forecast
23.2.1 Malaysia Pap Smear Test Market
23.2.2 Malaysia HPV DNA Test Market

24. India - Cervical Cancer Test Analysis
24.1 India - Cervical Cancer Test (Screening) Population & Forecast
24.1.1 India Pap Smear Test Population
24.1.2 India HPV DNA Test Population
24.1.3 India VIA Test Population
24.2 India Cervical Cancer Test (Screening) Market & Forecast
24.2.1 India Pap Smear Test Market
24.2.2 India HPV DNA Test Market
24.2.3 India VIA Test Market

25. China - Cervical Cancer Test Analysis
25.1 China - Cervical Cancer Test (Screening) Population & Forecast
25.1.1 China Pap Smear Test Population
25.1.2 China HPV DNA Test Population
25.1.3 China VIA Test Population
25.2 China - Cervical Cancer Test (Screening) Market & Forecast
25.2.1 China Pap Smear Test Market
25.2.2 China HPV DNA Test Market
25.2.3 China VIA Test Market

26. Thailand - Cervical Cancer Test Analysis
26.1 Thailand - Cervical Cancer Test (Screening) Population & Forecast
26.1.1 Thailand Pap Smear Test Population
26.1.2 Thailand VIA Test Population
26.2 Thailand Cervical Cancer Test (Screening) Market & Forecast
26.2.1 Thailand Pap Smear Test Market
26.2.2 Thailand VIA Test Market

27. Indonesia - Cervical Cancer Test Analysis
27.1 Indonesia Cervical Cancer Test (Screening) Population & Forecast
27.1.1 Indonesia Pap Smear Test Population
27.1.2 Indonesia HPV DNA Test Population
27.1.3 Indonesia VIA Test Population
27.1.4 Indonesia Pap Smear & VIA Test Population
27.2 Indonesia Cervical Cancer Test (Screening) Market & Forecast
27.2.1 Indonesia Pap Smear Test Market
27.2.2 Indonesia HPV DNA Test Market
27.2.3 Indonesia VIA Test Market
27.2.4 Indonesia Pap smear & VIA Test Market

28. Rest of World - Cervical Cancer Test Analysis
28.1 Rest of World Cervical Cancer Test (Screening) Population & Forecast
28.1.1 Rest of World Pap smear Test Population
28.1.2 Rest of World HPV DNA Test Population
28.2 Rest of World Cervical Cancer Test (Screening) Market & Forecast
28.2.1 Rest of World Pap Smear Test Market
28.2.2 Rest of World HPV DNA Test Market

29. Growth Drivers
29.1 Introduction of Low Cost VIA Test
29.1.1 Countries Offering VIA Test via National Programs
29.1.2 Countries Offering VIA Test via Pilot Programs
29.2 Worldwide High Prevalence of HPV Infected Patients
29.3 Rising Number of Incidence of Cervical Cancer in United Kingdom
29.4 Worldwide Rising Incidence of Teenage Sexual Cases

30. Challenges
30.1 Lack of Appropriate Healthcare Infrastructure
30.2 Introduction of HPV Vaccination Programs Worldwide
Note: Product cover images may vary from those shown
3 of 4
  • Canada
  • China
  • France
  • Germany
  • India
  • Indonesia
  • Italy
  • Japan
  • Korea
  • Malaysia
  • Netherlands
  • Norway
  • Singapore
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom
  • United States
Note: Product cover images may vary from those shown
4 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll